Compare
Genpact Ltd vs FTI Consulting, Inc vs Astrana Health, Inc. vs Booz Allen Hamilton Holding Corp
| Latest fiscal year | Genpact Ltd G | FTI Consulting, Inc FCN | Astrana Health, Inc. ASTH | Booz Allen Hamilton Holding Corp BAH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-31 |
| Revenue | $5.08B | $3.79B | $3.18B | $11.22B |
| Revenue growth (YoY) | +6.6% | +2.4% | +56.4% | -6.4% |
| Gross margin | 36.0% | 32.1% | n/a | 52.7% (computed) |
| Operating margin | 14.8% | 10.3% | 2.5% | 9.2% |
| Net margin | 10.9% | 7.1% | 0.7% | 7.6% |
| Net income | $552.49M | $270.87M | $22.49M | $851.00M |
| EPS (Diluted) | $3.13 | $8.24 | $0.46 | $6.90 |
| Operating cash flow | $812.86M | $152.13M | $114.60M | $1.04B |
| Free cash flow | $734.65M | $93.60M | $104.49M | $951.00M |
| Cash & equivalents | $853.84M | $265.09M | $429.47M | $728.00M |
| Total assets | $5.84B | $3.49B | $2.22B | $7.12B |
| Total liabilities | $3.29B | $1.76B | $1.66B | $6.01B |
| Shareholders' equity | $2.55B | $1.73B | $779.29M | $1.10B |
| Return on year-end equity | 21.7% | 15.6% | 2.9% | 77.0% |
| Shares outstanding | 170.34M | 30.86M | 48.89M | 120.34M |
Revenue, most recent five fiscal years
| Fiscal year | Genpact Ltd | FTI Consulting, Inc | Astrana Health, Inc. | Booz Allen Hamilton Holding Corp |
|---|---|---|---|---|
| Latest | $5.08B Ended 2025-12-31 | $3.79B Ended 2025-12-31 | $3.18B Ended 2025-12-31 | $11.22B Ended 2026-03-31 |
| 1 year earlier | $4.77B Ended 2024-12-31 | $3.70B Ended 2024-12-31 | $2.03B Ended 2024-12-31 | $11.98B Ended 2025-03-31 |
| 2 years earlier | $4.48B Ended 2023-12-31 | $3.49B Ended 2023-12-31 | $1.39B Ended 2023-12-31 | $10.66B Ended 2024-03-31 |
| 3 years earlier | $4.37B Ended 2022-12-31 | $3.03B Ended 2022-12-31 | $1.14B Ended 2022-12-31 | $9.26B Ended 2023-03-31 |
| 4 years earlier | $4.02B Ended 2021-12-31 | $2.78B Ended 2021-12-31 | $773.91M Ended 2021-12-31 | $8.36B Ended 2022-03-31 |